Skip to main content
OpenTrials
Completed

NCT Number: NCT06060210

Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion

Postoperative depression is a perioperative psychological complication that severely affects patient recovery and quality of life. In extreme cases, it may lead to suicidal behavior. Postoperative depression can be seen in various surgical operations .

High rates of anxiety and depression have been reported in cohorts of patients with IIH, though it is not clear whether there is any direct relationship. Worse outcomes in terms of disability level and symptom resolution have been observed in IIH patients who have a known co-existing psychiatric illness compared to those who do not .

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–44 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Banha faculity of medicine

Banhā, Elqalyoubea, 13511, Egypt

About this study

Postoperative depression is a perioperative psychological complication that severely affects patient recovery and quality of life. In extreme cases, it may lead to suicidal behavior. Postoperative depression can be seen in various surgical operations.

Idiopathic intracranial hypertension (IIH) is the most common cause of papilledema and is typically seen in young women with elevated body mass index. The prevalence of IIH has been increasing in recent years, in parallel with climbing rates of obesity .

High rates of anxiety and depression have been reported in cohorts of patients with IIH, though it is not clear whether there is any direct relationship. Worse outcomes in terms of disability level and symptom resolution have been observed in IIH patients who have a known co-existing psychiatric illness compared to those who do not .

The use of lumbo-peritoneal (LP) shunts has been well documented as a treatment modality for patients with idiopathic intracranial hypertension (IIH). There are a number of advantages to LP shunts when compared with other treatment modalities for IIH, such as stereotactic ventriculo-peritoneal shunts (VP) and optic nerve sheath fenestrations (ONSF). LP shunts avoid intracranial risks, such as cerebral hemorrhage, seizures, and shunt malposition.

Over the past decade, it has been provoked a single administration of ketamine elicits fast (in as little as half an hour) and sustained antidepressant effects both in human and animal models of depression. There are some potential mechanisms of antidepressant actions of ketamine. MK-801, a noncompetitive NMDA receptor antagonist, produced antidepressant-like actions in the animal model of depression . Ketamine can also increase hippocampal brain-derived neurotrophic factor levels, which may be important for producing a rapid onset of antidepressant action .A recent study found ketamine could quickly elevate mood by blocking NMDAR receptor-dependent bursting activity of the lateral habenula neurons to disinhibit downstream monoaminergic reward centers and provide a framework for developing new rapid-acting antidepressants .

Accordingly, we hypothesized that intraoperative ketamine can reduce the post operative depressive symptoms after theco-peritoneal shunt insertion.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients of both sex
  • with an age range from 20 to 44 years old
  • having moderate to severe depressive symptoms
  • an expected hospital stay of no less than 7 days

Exclusion criteria

  • history of epilepsy
  • major depressive disorder patients
  • drug abuse
  • history of allergy to the research drug
  • heart rate > 120 beats per minute
  • systolic blood pressure > 180 mmHg
  • heart failure
  • renal or liver dysfunction
  • patients who cannot cooperate to complete psychiatric assessments
  • pregnant or breast-feeding women
  • patients who refuse to sign informed consent.

Treatment and study plan

normal saline

Drug

50-ml Saline

ketamine

Drug

50-ml volumes, and the ketamine concentration is 1 mg/ml

Other names: katalar

Primary outcomes

  1. the rate of response to treating postoperative depression

    Time frame: at 3 postoperative days

    defined as a relative reduction of more than 50% from the baseline 10-item MADRS score

Secondary outcomes

  1. The remission rate

    Time frame: at 1 and 3 days after the administration of ketamine.

    defined as an absolute value of MADRS score of no more than 10

  2. The incidence of severe pain

    Time frame: within the first 48 hours postoperatively

    From 0 to 10 (0 no pain , 10 very sever pain)

  3. The quality of life

    Time frame: within 7 days postoperatively

    a scale ranging from 100-0, where 100 is labeled 'Perfect quality of life,' and 0 is labeled 'Might as well be dead'.

Sponsors and collaborators

Lead sponsor

Benha University

Other

Registry information

Official study title

Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion. A Randomized Double-blind Controlled Trial.

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Sep 29, 2023
Registry last updated
Jan 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.